Clinical Trials Browser

Breast Neoplasms

Triple Negative Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Colonic Neoplasms

Colorectal Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Esophageal Neoplasms

Pathologic Complete Response, Breast Neoplasms

Hormone Receptor Positive Advanced Breast Cancer

Carcinoma, Transitional Cell

HER2-positive

Platinum-resistant Recurrent Ovarian Cancer

Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Stomach Neoplasms

Advanced Colorectal Cancer

Lymphoma, Extranodal NK-T-Cell

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Stomach Neoplasms

Leiomyosarcoma

Squamous Cell Carcinoma of Head and Neck, Nausea, Radiation Injuries, Vomiting

Breast Neoplasms, Cardiovascular Diseases

Triple Negative Breast Neoplasms

HER2-positive Breast Cancer

Lymphoma, Extranodal NK-T-Cell

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

Breast Neoplasms

Colonic Neoplasms

Small Cell Lung Carcinoma

Breast Neoplasms

Mesothelioma, Malignant

Advanced Breast Cancer

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Lymphoma, Recurrence

Carcinoma, Ovarian Epithelial

Triple Negative Breast Neoplasms

Rectal Neoplasms

Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

Rectal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Esophageal Neoplasms, Lung Neoplasms

Small Cell Lung Carcinoma

Nasopharyngeal Carcinoma

Hypopharyngeal Neoplasms

Colorectal Neoplasms

Stomach Neoplasms

Small Cell Lung Carcinoma

Ovarian Neoplasms

Small Cell Lung Carcinoma

Clinical Trials

HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection

Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology

Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

APPROVE

Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer

Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer

Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma

The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

Deep Inspiration Breath-hold Radiotherapy for Left-sided Breast Cancer

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

LM-HNSCC

Characteristics and Treatment Trends of Young Breast Cancer in China

The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts

Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer

Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant Reconstruction

Real World Study of MPM in China

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

RENI-1

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

STELLAR

Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma

Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma

A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Monitoring Efficacy of Radiotherapy in Lung Cancer and Esophageal Cancer

Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer

The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT

New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Efficacy and Safety of S-1 Plus Oxaliplatin in First-line Treatment of Ederly Patients With Advanced Gastric Cancer

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy